James Hardie Industries PLC ADR reached a 52-week high of $31.38 in trading, leaving the share price just 1% below its peak at $31.32. The stock has gained 56.17% over the past year and 46% year-to-date, with a near-44% surge over the past six months lifting the building-materials maker's market capitalization to roughly $17.6 billion.
The rally coincides with the progress of James Hardie's planned sale of its European business, Fermacell, to Holcim Group for approximately €840 million ($980 million). The transaction, which values the unit at 11.5 times FYE 2026 EBITDA, is expected to close in the first half of 2027 subject to customary conditions.
Several recent analyst actions underscored the optimism around the stock. Barclays upgraded James Hardie from Equalweight to Overweight, citing portfolio growth, pricing power and gains in market share. Oppenheimer raised its price target to $36.00 from $32.00 while maintaining an Outperform rating. Stephens initiated coverage with an Overweight rating and a $31.00 target, while Fitch Ratings affirmed a 'BBB' long-term issuer default rating and revised its outlook from negative to stable.
Data tracked by InvestingPro rates the company's financial health as good and notes that four analysts have recently revised earnings upward and net income is expected to grow this year. On valuation, however, the same screening flagged the stock as potentially overvalued relative to its fair value and placed it on a Most Overvalued list.
